Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.

ABSTRACT:

Context

Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control.

Objective

Our objective was to demonstrate the superiority of pasireotide LAR over octreotide LAR in medically naive patients with acromegaly.

Design and setting

We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries.

Patients

A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled. Patients either had previous pituitary surgery but no medical treatme

SUBMITTER: Colao A 

PROVIDER: S-EPMC3965714 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature